May 12, 2008 – VGX Pharmaceuticals (VGX) announced that the Company has signed a multi-year supply agreement to provide plasmid DNA to support the ongoing toxicology and clinical trials of the United Kingdom Cystic Fibrosis Gene Therapy Consortium comprising over 80 scientists and clinicians in Edinburgh, London and Oxford dedicated to the search for effective gene therapy to the lungs of those with Cystic Fibrosis. Under the terms of the agreement, VGX will provide multiple batches of a CFTR product to support clinical studies planned to run through 2010. If all options are exercised, several hundred grams of plasmid DNA will be provided, making this agreement one of the largest contracts for non-viral gene therapy products ever undertaken... VGX Pharmaceuticals' Press Release -
Showing posts with label VGX Pharmaceuticals. Show all posts
Showing posts with label VGX Pharmaceuticals. Show all posts
May 19, 2008
VGX Pharmaceuticals : multi-year production agreement with the United Kingdom Cystic Fibrosis Gene Therapy Consortium
May 12, 2008 – VGX Pharmaceuticals (VGX) announced that the Company has signed a multi-year supply agreement to provide plasmid DNA to support the ongoing toxicology and clinical trials of the United Kingdom Cystic Fibrosis Gene Therapy Consortium comprising over 80 scientists and clinicians in Edinburgh, London and Oxford dedicated to the search for effective gene therapy to the lungs of those with Cystic Fibrosis. Under the terms of the agreement, VGX will provide multiple batches of a CFTR product to support clinical studies planned to run through 2010. If all options are exercised, several hundred grams of plasmid DNA will be provided, making this agreement one of the largest contracts for non-viral gene therapy products ever undertaken... VGX Pharmaceuticals' Press Release -
Subscribe to:
Comments (Atom)
